http://www.medscape.com/viewarticle/748990
"Paul Bunn, MD, professor of medicine and James Dudley Chair in Cancer Research at the University of Colorado School of Medicine, in Aurora, who was on the panel, noted that the approval of crizotinib is part of a paradigm shift in the care and management of lung cancer."
"Mark G. Kris, MD, chief of the thoracic oncology service at Memorial Sloan-Kettering Cancer Center in New York City, noted that this is a 'fantastic development.' 'I see this as a delivery on the promise of personalized medicine and genomic medicine,' he said during the panel discussion. 'Clinical trials have shown that virtually every patient with an ALK fusion who received crizotinib has had some benefit. It is very effective.'"
No comments:
Post a Comment